PMID- 9679732
OWN - NLM
STAT- MEDLINE
DCOM- 19980804
LR  - 20190607
IS  - 1010-4283 (Print)
IS  - 1010-4283 (Linking)
VI  - 19
IP  - 4
DP  - 1998
TI  - Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the 
      proliferation of human breast cancer cell lines in vitro.
PG  - 229-37
AB  - The levels of several tumor-associated proteases, including plasminogen 
      activators (PA), are elevated in many malignant tumors compared to their benign 
      tumor counterparts. Extracellular matrix degradation mediated by PA may 
      facilitate tumor cell invasion and metastasis. In this study, the 
      anti-proliferative activities of anti-urokinase-type plasminogen activator 
      monoclonal antibodies (anti-UK MAbs) against human breast cancer cell lines were 
      tested. Immunofluorescence studies localized urokinase (UK) on the surfaces of 
      breast cancer cells. Inhibition studies showed that anti-UK MAb concentrations 
      exerted 50% inhibition of 3H-thymidine uptake by human breast cancer cell lines; 
      CRL-1500 and CRL-1504 were 5.6 x 10(-9)-1.82 x 10(-13) and 3.16 x 10(-10)-3.54 x 
      10(-12) M, respectively. Anti-UK MAbs exhibited little effect (10-20%) on normal 
      human lymphocyte and liver cell lines. Dye exclusion indicated that anti-UK MAbs 
      had a potent cytolytic effect on human breast cancer cells. Taken together, these 
      results demonstrated the potential of anti-UK MAbs to be a valuable reagent for 
      cancer immunotherapy and anti-metastatic therapy.
FAU - Abaza, M S
AU  - Abaza MS
AD  - Department of Neurosurgery, Baylor College of Medicine, Houston, Tex, USA.
FAU - Narayan, R K
AU  - Narayan RK
FAU - Atassi, M Z
AU  - Atassi MZ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Breast Neoplasms/*pathology
MH  - Cell Division/*drug effects
MH  - Cell Survival/drug effects
MH  - Humans
MH  - Tumor Cells, Cultured/drug effects/radiation effects
MH  - Urokinase-Type Plasminogen Activator/*immunology/metabolism
EDAT- 1998/07/29 02:04
MHDA- 2000/10/06 11:01
CRDT- 1998/07/29 02:04
PHST- 1998/07/29 02:04 [pubmed]
PHST- 2000/10/06 11:01 [medline]
PHST- 1998/07/29 02:04 [entrez]
AID - tbi19229 [pii]
AID - 10.1159/000030012 [doi]
PST - ppublish
SO  - Tumour Biol. 1998;19(4):229-37. doi: 10.1159/000030012.